Sunday, 10 February 2019 13:17

Anticoagulation news items. Week commencing 4th February 2019

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine
Cohort study of 352 patients with acute major bleeding associated with the use of a factor Xa inhibitor, reported that andexanet reduced anti–factor Xa activity by 93% from baseline, and that 82% of patients achieved haemostatic efficacy at 12 hours.


Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial

The Lancet
RCT reported no change in functional status at 90 days with intensive (target systolic BP 130–140 mm Hg within 1 h) or guideline-recommended (target <180 mm Hg) BP lowering therapy over 72 h in 2227 alteplase-eligible patients with acute ischaemic stroke.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: